A randomized trial comparing @entity3102 and @entity8701 prophylactic therapy in XXXX @entity1 .

@entity1 @entity5253 @entity3102 @entity364 @entity1398 @entity293 @entity8701
A randomized trial was conducted comparing @entity3102 and @entity8701 in the prevention of @entity5253 and appearance of invasive @entity364 in 51 @entity1398 @entity1 undergoing induction chemotherapy. @entity3102 was administered in a 200 mg dose twice daily. @entity8701 oral suspension was given in doses of 500,000 units four times daily. Surveillance cultures of the throat and urine were obtained prior to treatment and conducted weekly. @entity1 were enrolled in the study if the absolute granulocyte count was less than 1500/microliter, if physical examination revealed no evidence of @entity5253 , no evidence of @entity293 , and there was no pulmonary infiltrate on chest x-ray. @entity1 were continued on study until the absolute granulocyte count reached 1500/microliter, evidence of @entity5253 appeared, or presumed or proven invasive @entity364 appeared. Of the 46 evaluable @entity1 , 22 received @entity3102 , 3 (14%) developed @entity5253 , and 5 developed suspected @entity364 (23%). Of 24 @entity1 who received @entity8701 , 4 (17%) developed @entity5253 and 8 (33%) developed @entity364 , 4 proven and 4 suspected. Significantly more @entity1 on the @entity8701 arm progressed to invasive @entity364 . @entity3102 was not superior to @entity8701 in reducing the frequency of @entity5253 but possibly reduced the frequency of invasive @entity364 .
